564 related articles for article (PubMed ID: 37185393)
1. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Lochrin SE; Forde PM
Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
[TBL] [Abstract][Full Text] [Related]
7. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
8. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
Liu X; Xing H; Liu H; Chen J
Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
[TBL] [Abstract][Full Text] [Related]
9. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
10. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Sathiyapalan A; Baloush Z; Ellis PM
Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
12. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
Isaacs J; Stinchcombe TE
Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
Ann Thorac Surg; 2024 Feb; ():. PubMed ID: 38316378
[TBL] [Abstract][Full Text] [Related]
16. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
West HJ; Kim JY
JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
20. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
Sim JK; Choi J; Lee SY
Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]